GlassScriptPhysician profile
Ikram Hussain
NPI 1760492466
$4,201.15
in general payments reported to CMS, 2019-2025
26 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $1,043 · 2021: $730 · 2022: $385 · 2023: $534 · 2024: $196 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $645.26 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $503.01 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $456.97 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $385.06 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $364.02 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $298.84 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.52 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $206.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $154.41 | 2021-2023 | Trelegy Ellipta |
| Abbvie INC. | $151.60 | 2021-2025 | |
| Allergan, INC. | $116.43 | 2019-2020 | |
| Amgen INC. | $107.92 | 2023-2025 | Otezla, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.60 | 2020-2025 | Jardiance |
| Eisai INC. | $78.14 | 2020-2021 | |
| Exact Sciences Corporation | $67.14 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $62.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.24 | 2019 | |
| Hikma Pharmaceuticals USA | $36.63 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.57 | 2023 | |
| Genentech USA, INC. | $32.34 | 2020-2022 | |
| Atland Pharmaceuticals, LLC | $29.50 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Xeris Pharmaceuticals, INC. | $24.38 | 2022 | |
| Antares Pharma, INC. | $20.80 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.49 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $15.60 | 2022 | |
| Horizon Therapeutics Plc | $14.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikram Hussain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.